Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tislelizumab - BeiGene

Drug Profile

Tislelizumab - BeiGene

Alternative Names: BGB-A317

Latest Information Update: 24 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Celgene Corporation
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hodgkin's disease
  • Preregistration Urogenital cancer
  • Phase III Cancer; Gastric cancer; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer
  • Phase II Chronic lymphocytic leukaemia; Lung cancer; Lymphoma; Solid tumours
  • Phase I Ovarian cancer; Renal cancer

Most Recent Events

  • 24 Feb 2020 BeiGene plans a phase I/II trial for BGB 10188 and tislelizumab in mature B-cell lymphoma and Solid tumours (Combination therapy, Monotherapy, Metastatic disease, Second-line therapy) (PO) in March 2020 (NCT04282018)
  • 21 Jan 2020 BeiGene intends to file sNDA for Non-small cell lung cancer (First-line therapy) with NMPA in China
  • 21 Jan 2020 BeiGene intends to meet with Center for Drug Evaluation (CDE) at the National Medical Products Administration (NMPA) in China to discuss the possibility of a supplemental new drug application (sNDA) submission for tislelizumab for Non-small cell lung cancer (First-line therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top